NanoVibronix (NanoVibronix) Interest Expense : $-0.14 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is NanoVibronix Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. NanoVibronix's interest expense for the three months ended in Dec. 2023 was $ -0.03 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.14 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. NanoVibronix's Operating Income for the three months ended in Dec. 2023 was $ -0.70 Mil. NanoVibronix's Interest Expense for the three months ended in Dec. 2023 was $ -0.03 Mil. NanoVibronix did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

NanoVibronix Interest Expense Historical Data

The historical data trend for NanoVibronix's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NanoVibronix Interest Expense Chart

NanoVibronix Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.06

-0.15

-0.05

-0.35

-0.14

NanoVibronix Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-0.35	-0.03	-0.03	-0.04	-0.03

NanoVibronix Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.14 Mil.

NanoVibronix (NAS:NAOV) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

NanoVibronix's Interest Expense for the three months ended in Dec. 2023 was $-0.03 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-0.70 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $0.00 Mil.

NanoVibronix's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

NanoVibronix did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

NanoVibronix (NanoVibronix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NanoVibronix Inc (NAS:NAOV) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

56R0:Germany

Address

525 Executive Boulevard, Elmsford, New York, NY, USA, 10523

Website

https://www.nanovibronix.com

NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low frequency, low intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients as well as through distributor agreements.

Executives

Christopher M Fashek	director	8023 VANTAGE DR, SAN ANTONIO TX 78230
Stephen Russell Brown	officer: Chief Financial Officer	18-B NEIL COURT, OCEANSIDE NY 11572
Aurora Cassirer	director	C/O NANOVIBRONIX, INC.,, 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Maria Schroeder	director	C/O NANOVIBRONIX, INC.,, 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Brian M Murphy	director, officer: Chief Executive Officer	525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Michael Ferguson	director	525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Thomas Mika	director	TEGAL CORP, 2201 SOUTH MCDOWELL BLVD, PETALUMA CA 94954
Ira A Greenstein	director	IDT CORP, 520 BROAD STREET, NEWARK NJ 07102
Harold Jacob	director, officer: Chief Medical Officer	HAADMUR MEBUYON 26, HARNOT, JERUSALEM L3 95403
Martin M Goldstein	director	C/O NANOVIBRONIX, INC., 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
William Stern	director, officer: Chief Executive Officer	525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Jona Zumeris	director, officer: VP of Technology	105 MAXESS ROAD, SUITE S124, MELVILLE NY 11747
Miriam W Kelly	10 percent owner	P.O. BOX 1443, BROOKLANDVILLE MD 21022